一、 临床研究（8）
1. J Clin Oncol (IF: 32.956;Q1 )2020 Dec 17. DOI: 10.1200/JCO.20.01820Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial吉非替尼与长春瑞滨联合顺铂辅助治疗Ⅱ-Ⅲa期（N1-N2）EGFR突变NSCLC的比较：Ⅲ期临床研究CTONG1104的最终总体生存分析2. Lancet Respir Med (IF: 25.094; Q1) 2020 Dec 18. DOI: 10.1016/S2213-2600(20)30365-9Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial卡瑞利珠单抗联合卡铂和培美曲塞与单纯化疗治疗晚期非鳞状非小细胞肺癌化疗初治患者的比较（CameL）：一项随机、开放标签、多中心、3期试验3. J Thorac Oncol (IF: 13.357; Q1) 2020 Dec 14. DOI: 10.1016/j.jtho.2020.11.025Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial阿替利珠单抗联合化疗一线治疗非鳞状非小细胞肺癌：Ⅲ期随机临床试验IMpower132研究的结果4. Ann Oncol (IF: 18.274; Q1) 2020 Dec 1. DOI: 10.1016/j.annonc.2020.11.020Safety and Efficacy of Quavonlimab, a Novel Anti-CTLA-4 Antibody (MK-1308), in Combination with Pembrolizumab in First-Line Advanced Non-Small Cell Lung Cancer新型抗CTLA-4抗体Quavonlimab（MK-1308）联合帕博利珠单抗一线治疗晚期非小细胞肺癌的安全性和有效性5. Clin Cancer Res (IF: 10.107; Q1) 2020 Dec 1.DOI: 10.1158/1078-0432.CCR-20-2551Phase 1 and pharmacological study of olaparib in combination with high-dose radiotherapy with and without concurrent cisplatin for non-small cell lung cancer奥拉帕利联合大剂量放疗伴或不伴同步顺铂治疗非小细胞肺癌的1期及药理学研究6. Drugs (IF: 6.189; Q1) 2020 Dec 17. DOI: 10.1007/s40265-020-01441-6Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations一项比较达克替尼和吉非替尼一线治疗EGFR敏感突变的晚期非小细胞肺癌患者随机研究的最新总生存期7. JAMA Oncol (IF: 24.799; Q1) 2020 Dec 17. DOI: 10.1001/jamaoncol.2020.6332Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non-Small Cell Lung Cancer非小细胞肺癌患者放疗时冠状动脉左前降支放射剂量与主要心脏不良事件及死亡率的关系8. Lancet Oncol(IF: 33.752; Q1) 2020 Dec 4.DOI: 10.1016/S1470-2045(20)30539-8Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial度伐利尤单抗±替西木单抗+铂类/依托泊苷和单纯铂类/依托泊苷一线治疗广泛期小细胞肺癌的比较（CASPIAN）：一项随机、对照、开放标签、3期试验的最新结果
二、meta分析/综述（1）
9.Cochrane Database Syst Rev(IF: 7.89; Q1) 2020 Dec 14.DOI: 10.1002/14651858.CD013257.pub2Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer免疫检查点抑制剂单用或联合用药，相较铂类化疗联合或不联合贝伐珠单抗一线治疗晚期非小细胞肺癌的疗效对比
三、 基础研究/letters/评述（9）
10. Cancer Cell (IF: 26.602; Q1) 2020 Dec 17. DOI: 10.1016/j.ccell.2020.11.006DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity错配修复缺陷型肿瘤细胞的DNA识别对抗肿瘤免疫至关重要11. Cancer Cell (IF: 26.602; Q1) 2020 Dec 1. DOI: 10.1016/j.ccell.2020.11.005Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade免疫原性化疗结合检查点阻断可增强对肺癌的CAR-T细胞招募并提高抗肿瘤功效12. Cancer Res(IF: 9.727; Q1) 2020 Dec 8. DOI: 10.1158/0008-5472.CAN-20-1885Targeting MARCO and IL-37R on immunosuppressive macrophages in lung cancer blocks regulatory T cells and supports cytotoxic lymphocyte function肺癌免疫抑制巨噬细胞靶向MARCO和IL-37R阻断调节性T细胞并支持细胞毒性淋巴细胞功能13. Cancer Discov(IF: 29.497; Q1) 2020 Dec 11. DOI: 10.1158/2159-8290.CD-RW2020-179A Lung Cancer Subtype Depends on the Hexosamine Biosynthesis Pathway14. J Thorac Oncol (IF: 13.357; Q1) 2020 Dec 17. DOI: 10.1016/j.jtho.2020.11.008Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in Non-Small Cell Lung Cancer使用放射敏感性和正常组织毒性相关基因组标记来个性化确定非小细胞肺癌放射剂量15. J Thorac Oncol (IF: 13.357; Q1) 2020 Dec 8. DOI: 10.1016/j.jtho.2020.11.021A Gene Mutation Signature Predicting Immunotherapy Benefits in Non-Small Cell Lung Cancer Patients一个能预测非小细胞肺癌患者免疫治疗疗效的基因突变特征16. J Thorac Oncol (IF: 13.357; Q1) 2020 Dec 9. DOI: 10.1016/j.jtho.2020.11.017Genetic Heterogeneity of MET-aberrant Non-Small Cell Lung Cancer and its Impact on the Outcome of ImmunotherapyMET异常非小细胞肺癌的基因异质性及其对免疫治疗预后的影响17. Clin Cancer Res (IF: 10.107; Q1) 2020 Dec 1. DOI: 10.1158/1078-0432.CCR-20-2081Biomarkers of osimertinib response in patients with refractory, EGFR-T790M-positive non-small cell lung cancer and central nervous system metastases:the APOLLO study难治性EGFR-T790M阳性非小细胞肺癌脑转移患者对奥希替尼治疗反应的生物标志物：APOLLO研究18. JAMA Surg(IF: 13.625; Q1) 2020 Dec 23. DOI: 10.1001/jamasurg.2020.5601A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma
简评：本期肺癌月报列出了12项新开的临床试验（观察性研究和诊断相关研究除外）：一线治疗方面，帕博利珠单抗+仑伐替尼、度伐利尤单抗针对中国人群的布局值得关注；二线及以上治疗，针对三代奥希替尼治疗失败的患者、PD1/PD-L1治疗失败的患者、METex14跳跃中国患者的临床试验值得关注；在SCLC方面，国产药物的布局值得持续关注。
NextMed是一个创新的知识数据库，专注于未满足的临床需求，收集并整合临床指南、临床试验和学术文献数据，构建起独特的适应证图谱和循证数据标准，当前收录全部肿瘤领域内的疾病、治疗、药物安全性、临床试验设计、关键临床结果等数据。NextMed已与医药魔方数据标准打通，并和NextPharma等产品形成良好数据生态，提供临床用药、适应症选择、临床研究分析、药物疗效-安全性-经济性评估等数据。
